BNP Paribas Financial Markets Has $27.35 Million Stake in STERIS plc (NYSE:STE)

BNP Paribas Financial Markets decreased its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,766 shares of the medical equipment provider's stock after selling 9,563 shares during the period. BNP Paribas Financial Markets owned about 0.11% of STERIS worth $27,350,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its stake in STERIS by 13.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider's stock valued at $1,414,453,000 after buying an additional 778,613 shares in the last quarter. Impax Asset Management Group plc boosted its stake in shares of STERIS by 29.7% in the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider's stock valued at $251,663,000 after purchasing an additional 263,383 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of STERIS by 9.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock valued at $270,230,000 after purchasing an additional 96,336 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of STERIS by 12.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider's stock worth $184,439,000 after purchasing an additional 95,412 shares during the last quarter. Finally, Raymond James & Associates increased its position in shares of STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider's stock worth $194,309,000 after purchasing an additional 12,005 shares in the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Trading Up 0.7 %

Shares of STE traded up $1.59 during trading hours on Friday, hitting $219.06. 342,972 shares of the stock traded hands, compared to its average volume of 497,351. The business has a fifty day moving average of $225.01 and a 200-day moving average of $228.28. The firm has a market capitalization of $21.62 billion, a PE ratio of 50.01 and a beta of 0.85. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the prior year, the company posted $2.03 EPS. The company's revenue was up 7.3% compared to the same quarter last year. Analysts expect that STERIS plc will post 9.15 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is presently 52.05%.

Wall Street Analysts Forecast Growth

STE has been the topic of several research analyst reports. Piper Sandler raised shares of STERIS from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Stephens reiterated an "overweight" rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. KeyCorp increased their target price on STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a report on Tuesday, September 3rd. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a report on Monday, November 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $253.00.

Insider Buying and Selling at STERIS

In related news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 35.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Cary L. Majors sold 1,682 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company's stock, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.